Natco Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Natco Pharma's recent management commentary highlights a challenging landscape marked by significant revenue declines due to loss of exclusivity on key products, which is expected to pressure margins and affect market perception. However, the company anticipates future growth driven by new product launches and strategic partnerships, which could stabilize revenue in the medium term. Vista's financial outlook reflects this cautious optimism, projecting early revenue recovery despite ongoing margin pressures, with a fair valuation aligned with intrinsic value. The competitive environment remains intense, particularly with rising R&D costs and pricing pressures, yet the expanding demand for contract manufacturing services presents opportunities for Natco. Over the next 12-24 months, key opportunities include leveraging new product introductions and enhancing partnerships, while watchpoints include the impact of competitive dynamics and raw material supply constraints on margins. Overall, Natco Pharma's outlook is shaped by a blend of recovery potential and ongoing challenges, necessitating close monitoring of execution on growth initiatives
Why We Like This Stock
- New product launches and strategic partnerships are expected to support moderate revenue growth
- The company's conservatively financed balance sheet provides stability amid market pressures
- The expanding demand for contract manufacturing services offers potential growth opportunities
Things To Watch Out For
- Significant revenue decline due to loss of exclusivity is impacting margins and market perception
- Increased competition and R&D costs are exerting pressure on profitability
- Raw material supply constraints may hinder production and margin recovery
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,999 | 4,430 | 4,078 | 3,387 | 3,766 |
| Profit Before Tax (Cr.) | 1,677 | 2,290 | 1,491 | 652 | 891 |
| PBT Margin | 41.9% | 51.7% | 3656.2% | 19.3% | 23.7% |
| Net Profit (Cr.) | 1,359 | 1,852 | 1,233 | 519 | 710 |
| Earnings Per Share | 38.0 | 51.8 | 34.4 | 14.5 | 19.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ► Hold | 1,000 | 01-Jun-2026 |
| Investec | ▲ Buy | 1,220 | 02-Jun-2026 |
Company Overview
Show Company Profile
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.